Mobile

Effects of once-daily administered GLP-1 Receptoragonist Lixisenatide in combination with basal Insulin on glycemic control in patients with type-2 diabetes mellitus not achieving therapeutic targets ...

Mise à jour : Il y a 5 ans
Référence : EUCTR2013-005334-37

Effects of once-daily administered GLP-1 Receptoragonist Lixisenatide in combination with basal Insulin on glycemic control in patients with type-2 diabetes mellitus not achieving therapeutic targets with premixed insulin strategy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Introduction of basal insulin therapy in combination with the GLP-1 receptor agonist Lixisenatide in patients with type-2 diabetes previously treated with premixed insulin not achieving therapeutic target will be associated with positive effects on glycemic control: - Changes in HbA1c from baseline to end

Critère d'inclusion

  • 10 patients (both gender) under treatment with premixed insulin (2-3 injections) and HbA1c>7% will be switched to basal insulin glargine (Lantus, once daily) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily)

Liens